文献速递淋巴瘤

伊布替尼联合标准免疫化疗治疗年轻高危弥漫大B细胞淋巴瘤:GLA二期研究

Ibrutinib and standard immunochemotherapy in younger, high-risk patients with diffuse large B-cell lymphoma: A phase II study of GLA.
PubMed 文献 · Br J Haematol · 2026-10-23

该前瞻性二期研究评估伊布替尼联合R-CHOEP方案治疗18-60岁、年龄调整国际预后指数≥2的弥漫大B细胞淋巴瘤患者,主要终点为2年无进展生存期。结果显示2年PFS为83%,与历史对照R-CHOEP单药治疗的75%相比无统计学差异(p=0.237),研究提前终止,结论仅为探索性。

要点

  • 伊布替尼联合R-CHOEP在年轻高危DLBCL中显示鼓励性活性,2年PFS达83%。
  • 与历史对照R-CHOEP单药相比,2年PFS无显著差异(83% vs 75%,p=0.237)。
  • ≥3级血液学不良事件常见,但无治疗相关死亡。

核心结论

  • 在提前终止的二期研究中,伊布替尼联合R-CHOEP显示出鼓励性活性,但结果仅为探索性和假设生成性。

研究设计与样本

  • 患者接受伊布替尼(560 mg每日,第1-112天)联合8周期R-CHOEP(每2周一次)。
  • 主要终点为2年无进展生存期,并与R-MegaCHOEP三期试验中符合相同入选标准、接受R-CHOEP单药治疗的患者(n=130)进行探索性比较。

主要发现

  • 总体缓解率为92%。
  • 中位随访31个月,2年无进展生存期为83%(95% CI,71-95),历史对照R-CHOEP单药为75%(95% CI,67-82),p=0.237。
  • 探索性细胞起源分析提示活化B细胞型疾病预后较好,但结果仅为描述性。
  • ≥3级血液学不良事件常见,但无治疗相关死亡。

临床怎么用

  • 目前不建议在年轻高危DLBCL中常规添加伊布替尼至R-CHOEP,需等待进一步验证。

局限性

  • 与历史对照的比较为探索性,非随机对照。
  • 细胞起源分析结果仅为描述性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Younger patients with high-risk diffuse large B-cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOEP+I) in patients aged 18-60 years with DLBCL and age-adjusted international prognostic index ≥2. Patients received ibrutinib (560 mg daily, d1-112) combined with eight cycles of R-CHOEP q2w. The primary end-point was 2-year progression-free survival (PFS). Outcomes were compared exploratorily with those of patients with identical inclusion criteria treated with R-CHOEP alone in the R-MegaCHOEP phase III trial (n = 130). Forty patients started R-CHOEP+I. Ibrutinib was administered for a median of 96 days, and 42% of patients completed treatment fully according to protocol. The overall response rate was 92%. Sixty-eight per cent received all R-CHOEP cycles compared with 88% in R-MegaCHOEP; 22% vs. 49% of patients with bulky and/or extranodal disease underwent radiotherapy. With a median follow-up of 31 months, 2-year PFS was 83% (95% CI, 71-95) vs. 75% (95% CI, 67-82) after R-CHOEP alone (p = 0.237). Exploratory cell-of-origin analyses suggested favourable outcomes in activated B-cell-type disease, but these findings remain descriptive. Grade ≥3 haematological adverse events were frequent, although no treatment-related deaths occurred. In this prematurely closed phase II study, the addition of ibrutinib to R-CHOEP showed encouraging activity. However, findings remain exploratory and hypothesis generating only.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shumilov E, Ziepert M, Friedrichs B, et al. Ibrutinib and standard immunochemotherapy in younger, high-risk patients with diffuse large B-cell lymphoma: A phase II study of GLA. Br J Haematol. 2026. PMID: 42920094. doi:10.1111/bjh.70902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。